Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island2Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts4Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis5Melvin.
JAMA Dermatol. 2014 Sep;150(9):957-63. doi: 10.1001/jamadermatol.2013.9957.
Individuals with psoriasis have an elevated risk of hypertension, and antihypertensive medications, especially β-blockers, have been linked to psoriasis development. However, the association of prior existing hypertension and antihypertensive medications with risk of incident psoriasis has not been assessed using prospective data.
To evaluate the association of hypertension and antihypertensive medications with risk of psoriasis.
DESIGN, SETTING, AND PARTICIPANTS: We performed a prospective cohort study (June 1, 1996, to June 1, 2008) of 77 728 US women from the Nurses' Health Study who provided biennially updated data on hypertension and antihypertensive medications.
Physician-diagnosed psoriasis.
A total of 843 incident psoriasis cases were documented during 1 066 339 person-years of follow-up. Compared with normotensive women, women with a hypertension duration of 6 years or more were at a higher risk of developing psoriasis (hazard ratio [HR], 1.27; 95% CI, 1.03-1.57). In stratified analysis, the risk of psoriasis was higher among hypertensive women without medication use (HR, 1.49; 95% CI, 1.15-1.92) and among hypertensive women with current medication use (HR, 1.31; 95% CI, 1.10-1.55) when compared with normotensive participants without medication use. Compared with women who never used β-blockers, the multivariate HRs for psoriasis for women who regularly used β-blockers were 1.11 (95% CI, 0.82-1.51) for 1 to 2 years of use, 1.06 (95% CI, 0.79-1.40) for 3 to 5 years of use, and 1.39 (95% CI, 1.11-1.73) for 6 years or more of use (P for trend = .009). No association was found between use of other individual antihypertensive drugs and risk of psoriasis.
Long-term hypertensive status is associated with an increased risk of psoriasis. Long-term regular use of β-blockers may also increase the risk of psoriasis.
患有银屑病的个体患高血压的风险增加,并且降压药物,特别是β受体阻滞剂,与银屑病的发展有关。然而,先前存在的高血压和降压药物与新发银屑病风险之间的关联尚未使用前瞻性数据进行评估。
评估高血压和降压药物与银屑病风险之间的关系。
设计、设置和参与者:我们进行了一项前瞻性队列研究(1996 年 6 月 1 日至 2008 年 6 月 1 日),纳入了来自美国护士健康研究的 77728 名女性,这些女性每两年更新一次高血压和降压药物的数据。
医生诊断的银屑病。
在 1066339 人年的随访中,共记录了 843 例新发银屑病病例。与血压正常的女性相比,高血压病程 6 年或以上的女性发生银屑病的风险更高(风险比 [HR],1.27;95%置信区间 [CI],1.03-1.57)。在分层分析中,与未使用药物的高血压女性相比,未使用药物的高血压女性(HR,1.49;95%CI,1.15-1.92)和正在使用药物的高血压女性(HR,1.31;95%CI,1.10-1.55)发生银屑病的风险更高。与从未使用过β受体阻滞剂的女性相比,经常使用β受体阻滞剂的女性患银屑病的多变量 HR 分别为:使用 1 至 2 年为 1.11(95%CI,0.82-1.51)、使用 3 至 5 年为 1.06(95%CI,0.79-1.40)和使用 6 年或更长时间为 1.39(95%CI,1.11-1.73)(趋势 P =.009)。未发现使用其他单一降压药物与银屑病风险之间存在关联。
长期高血压状态与银屑病风险增加有关。长期定期使用β受体阻滞剂也可能增加患银屑病的风险。